There is a growing body of evidence on targeting deregulated intracellular pathways, such as the hyperactivation of WNT–β-catenin, PI3K/Akt, or RAS signaling, although it has been shown that inhibiting these pathways has often not been effective in the clinical management of CRC [7,8,9,10]. This evidence concerns the gene AKT1 and colorectal carcinoma.